Last reviewed · How we verify

Acute monocytic leukemia — Treatment Landscape & Competitive Intelligence

Acute monocytic leukemia (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute monocytic leukemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cytoxan (Lyophilized) cyclophosphamide Baxter Alkylating agent Tumor cell DNA 1959-01-01
Cyclophosphamid Cyclophosphamid Zhejiang University Cytochrome P450 3A4

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Baxter · 2 drugs in Acute monocytic leukemia
  2. Zhejiang University · 1 drug in Acute monocytic leukemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute monocytic leukemia:

Cite this brief

Drug Landscape (2026). Acute monocytic leukemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-monocytic-leukemia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing